Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Appointment of CFO and Resignation of Interim FO
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's board, at its meeting on March 27, 2026, approved major leadership changes effective April 1, 2026, linked to the ongoing integration of Biocon Biologics with Biocon Limited. CEO & Managing Director Siddharth Mittal resigned effective March 31, 2026 to take up another role within the Biocon Group. He will be replaced by Shreehas Tambe, currently CEO & MD of Biocon Biologics, who will serve as CEO & MD for a 5-year term. Interim CFO Mukesh Kamath also stepped down effective March 31, 2026, with Kedar Upadhye, current CFO of Biocon Biologics, appointed as the new CFO. Additionally, 7 senior management personnel (including the CCO, CSO, COO, and Head of HR) ceased their roles, while new leaders from Biocon Biologics were designated as KMPs and senior management at Biocon Limited.
The leadership overhaul signals the merger integration with Biocon Biologics is moving forward, with experienced internal Group leaders taking the top roles to ensure continuity. Investors may find this reassuring for execution, though the sweeping senior management changes could create short-term transition risk.